Normoftal, Vilon and Visoluten all come from the same St Petersburg bioregulator programme, and two of them are linked to the eye. The names suggest three different compounds. On the published record, two of them are the same molecule and the third has no published sequence at all. This guide sorts out what each name refers to. For the evidence in detail, see our Normoftal research overview.
The names at a glance
| Name | What it is | Published sequence | Organ the developers assign |
|---|---|---|---|
| Normoftal | Synthetic dipeptide, 275 Da | Lys-Glu (KE) | Retina |
| Vilon | Synthetic dipeptide, 275 Da | Lys-Glu (KE) | Thymus and immune system |
| Visoluten | Peptide complex described on labels as from eye tissue | None published | Eye |
| Retinalamin | Polypeptide extract of animal retinas, used clinically in Russia | A mixture, no single sequence | Retina |
| Epitalon | Synthetic tetrapeptide, 390 Da | Ala-Glu-Asp-Gly (AEDG) | Pineal gland; also studied on the retina |
Sequences and masses for Normoftal, Vilon and Epitalon are from the developer's 2014 review (Khavinson, 2014), Table 1.
Normoftal and Vilon: two names, one molecule
The 2014 review lists both "Vilon (KE)" and "Normoftal (KE)" at 275 Da. KE is lysine joined to glutamic acid, formula C11H21N3O5. PubChem's record for that dipeptide (CID 7010502) lists Vilon and Normophthal among its synonyms, with CAS number 45234-02-4.
The developers' model holds that short peptides act on particular organs, so the same dipeptide is presented for the thymus as Vilon and for the retina as Normoftal. Nothing in the published chemistry distinguishes them. A lab test of the powder can confirm that a vial holds KE at the right mass and purity; it cannot tell which name it was sold under. Our Vilon research article covers the wider KE evidence.
Visoluten: no published sequence
Visoluten is a different kind of product. Russia's RLS drug reference lists it as a dietary supplement (BAA) and a source of peptides, without a composition (RLS). Retail labels describe a peptide complex from eye tissue. We found no published sequence, mass or peer-reviewed study of Visoluten, and PubMed has no paper under that name.
Synthetic short peptides vs extracts
The programme makes two kinds of product. Extracts such as Retinalamin and Thymalin are mixtures of peptides purified from animal organs. Short synthetic peptides, which the group calls cytogens, are made from amino acids and have one defined sequence. A 2019 review from the group says KE and AEDG were designed from an amino acid analysis of Retinalamin (Khavinson et al., 2019).
The difference matters for testing. A synthetic dipeptide can be checked for identity and purity against its known mass. An extract has no single structure to confirm, so a certificate can describe it but not verify a sequence.
Which eye studies used which compound
- KE (Normoftal, Vilon): cultures of embryonic retinal cells, where KE and AEDG increased markers of retinal neuron and pigment epithelium differentiation (Khavinson et al., 2013). Cell culture only.
- Epitalon (AEDG): the same cell cultures, plus studies in Campbell rats, a strain with inherited retinal degeneration (Khavinson et al., 2003), and a 2002 report in patients.
- Retinalamin: cell studies and Russian clinical reports, often combined with other extracts.
- Visoluten: nothing published that we could find.
All of this comes from one research network, and none of it is a placebo-controlled trial of KE.
What a Normoftal listing should state
Because the name alone does not identify the molecule, a useful listing for research use gives the sequence (Lys-Glu, or H-Lys-Glu-OH), the formula (C11H21N3O5) and the molecular mass (275.3 Da), so that an independent lab test can confirm identity. Our independent lab tests page explains what such a test can show.
A Normoftal 10mg research vial is coming soon to Peptx. See the Normoftal profile to join the waitlist, or browse bioregulator research compounds and our guide to Khavinson bioregulators.
References
- Khavinson VKh. "Peptides, genome, aging." Advances in Gerontology. 2014;4:337-345. DOI 10.1134/S2079057014040134
- Khavinson VKh, et al. "Peptidegic regulation of differentiation of embryonic retinal cells." Bulletin of Experimental Biology and Medicine. 2013. PubMed 23667897
- Khavinson V, et al. "Molecular-Physiological Aspects of Regulatory Effect of Peptide Retinoprotectors." Stem Cell Reviews and Reports. 2019. PubMed 30859383
- Khavinson VKh, et al. "Retinoprotective effect of Epithalon in campbell rats of various ages." Bulletin of Experimental Biology and Medicine. 2003. PubMed 12910293
- PubChem. Lys-Glu (lysylglutamic acid), CID 7010502. PubChem
- RLS encyclopedia (Russia). Visoluten and Normoftal entries. RLS: Visoluten, RLS: Normoftal